A Phase 2 interventional study of Gemcitabine and Carboplatin in Breast Cancer, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-11-20.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.
Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 23rd largest by enrollment of the 90 interventional ones that give a count, is one of 10 that started in 2004, is one of 65 in phase 2, and was the 22nd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Margaret Gatti-Mays · Sites in United States
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 73 · Phase 3 19
First in 1997; this study’s year is marked. 10 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 68 across the 90 interventional studies. Of the 78 that completed or were terminated, 34 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 95 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 38th largest by enrollment of the 80 interventional ones that give a count, is one of 5 that started in 2004, is one of 41 in phase 2, and was the 11th registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
1 of the studies testing gemcitabine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06026657Margaret Gatti-MaysGemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies testing gemcitabine in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purposes of this study are to determine the safety of gemcitabine and paraplatin either with or without trastuzumab Any side effects that might be associated with these compounds. Whether the two or three drugs listed above when given in combination can help patients with metastatic breast cancer. How long the treatment will stop the growth of the cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Human Epidermal growth factor Receptor 2 positive (HER2+): Gemcitabine + Carboplatin + Herceptin.
Drug: Gemcitabine · Drug: Carboplatin · Drug: Herceptin
Human Epidermal growth factor Receptor 2 negative (HER2-): Gemcitabine + Carboplatin. (Taxane-naive patients).
Drug: Gemcitabine · Drug: Carboplatin
Human Epidermal growth factor Receptor 2 negative (HER2-): Gemcitabine + Carboplatin. (Taxane-pretreated patients).
Drug: Gemcitabine · Drug: Carboplatin
Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion)
Also known as: Gemzar
Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion).
Also known as: Paraplatin
Day 1 of 14 day cycle (Cycle 1): 8 milligrams per kilogram (mg/kg) intravenous (IV) (90 minute infusion). Day 1 of 14 day cycle (Cycles 2-9): 4 mg/kg IV (30 minute infusion). Day 1 of 21 day cycle (Cycles 10+): 6 mg/kg IV (30 minute infusion).
Overall Tumor Response
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
Time frame: baseline to disease progression/recurrence (up to 3.5 years)
Duration of Response
Among tumor responders, the duration of tumor response is measured from the date of response (complete response \[CR\] or partial response \[PR\]) until the first date of documented progression or death from any cause. Duration of tumor response will be censored at the date of the last follow-up visit for tumor responders who are still alive and who have not progressed.
Time frame: date of response (CR or PR) until the first date of documented progression or death from any cause (up to 3.5 years)
Number of Patients Who Experienced Alopecia
Time frame: Baseline to 3.5 years
Time to Disease Progression (TTP)
If a patient is lost to follow-up, the patient will be censored as of the last date of contact. Patients who start a new treatment before they progress will be censored as of the date of start of the new treatment. If a patient died due to reason other than study disease, and patient has not progressed or received any new treatment, TTP is censored at the date of death.
Time frame: randomization date to the earliest date of the first documented disease progression date or the date of death if the patient dies due to study disease (up to 3.5 years)
Percentage of Patients With Overall Survival at 1 Year and 2 Years
Kaplan-Meier estimates of overall survival (percentage of patients surviving) at 1 year and 2 years.
Time frame: 1 Year, 2 Years
| Milestone | HER2+ | HER2- (Taxane-) | HER2- (Taxane+) |
|---|---|---|---|
| Started | 50 | 51 | 49 |
| Received at least one dose of study drug | 50 | 48 | 47 |
| Completed | 43 | 37 | 35 |
| Not completed | 7 | 14 | 14 |
| Withdrew: Withdrawal by subject | 2 | 3 | 5 |
| Withdrew: Physician decision | 2 | 9 | 6 |
| Withdrew: Sponsor decision | 1 | 0 | 0 |
| Withdrew: Ineligible | 0 | 1 | 0 |
| Withdrew: Reason not specified | 2 | 1 | 3 |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
| participants | HER2+ | HER2- (Taxane-) | HER2- (Taxane+) |
|---|---|---|---|
| Complete Response (CR) | 6 | 0 | 1 |
| Partial Response (PR) | 26 | 13 | 15 |
| Stable Disease (SD) | 12 | 20 | 13 |
| Progressive Disease (PD) | 4 | 12 | 17 |
| Not Evaluable (NE) | 2 | 2 | 1 |
Among tumor responders, the duration of tumor response is measured from the date of response (complete response \[CR\] or partial response \[PR\]) until the first date of documented progression or death from any cause. Duration of tumor response will be censored at the date of the last follow-up visit for tumor responders who are still alive and who have not progressed.
| months | HER2+ | HER2- (Taxane-) | HER2- (Taxane+) |
|---|---|---|---|
| Duration of Response | 6.9 (2.0 to 42.1) | 6.4 (3.5 to 29.7) | 5.6 (2.3 to 14.8) |
| participants | HER2+ | HER2- (Taxane-) | HER2- (Taxane+) |
|---|---|---|---|
| Number of Patients Who Experienced Alopecia | 21 | 17 | 16 |
If a patient is lost to follow-up, the patient will be censored as of the last date of contact. Patients who start a new treatment before they progress will be censored as of the date of start of the new treatment. If a patient died due to reason other than study disease, and patient has not progressed or received any new treatment, TTP is censored at the date of death.
| months | HER2+ | HER2- (Taxane-) | HER2- (Taxane+) |
|---|---|---|---|
| Time to Disease Progression (TTP) | 7.2 (6.0 to 9.0) | 5.6 (3.3 to 7.2) | 4.6 (1.8 to 9.0) |
Kaplan-Meier estimates of overall survival (percentage of patients surviving) at 1 year and 2 years.
| percentage of participants | HER2+ | HER2- (Taxane-) | HER2- (Taxane+) |
|---|---|---|---|
| 1 Year Overall Survival | 90.0 | 67.5 | 47.8 |
| 2 Year Overall Survival | 73.3 | 41.4 | 20.5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HER2+ | — | 10/50 (20%) | 50/50 (100%) |
| HER2- (Taxane-) | — | 11/48 (22.9%) | 48/48 (100%) |
| HER2- (Taxane+) | — | 10/47 (21.3%) | 45/47 (95.7%) |
| Event | HER2+ | HER2- (Taxane-) | HER2- (Taxane+) |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/50 | 4/48 | 2/47 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/50 | 4/48 | 2/47 |
| NeutropeniaBlood and lymphatic system disorders | 0/50 | 2/48 | 1/47 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/50 | 2/48 | 0/47 |
| PyrexiaGeneral disorders | 0/50 | 2/48 | 0/47 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/50 | 0/48 | 1/47 |
| Intestinal obstructionGastrointestinal disorders | 0/50 | 0/48 | 1/47 |
| NauseaGastrointestinal disorders | 1/50 | 0/48 | 1/47 |
| OesophagitisGastrointestinal disorders | 0/50 | 0/48 | 1/47 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/50 | 0/48 | 1/47 |
| Event | HER2+ | HER2- (Taxane-) | HER2- (Taxane+) |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 35/50 | 37/48 | 28/47 |
| FatigueGeneral disorders | 37/50 | 35/48 | 30/47 |
| NauseaGastrointestinal disorders | 27/50 | 33/48 | 22/47 |
| AnaemiaBlood and lymphatic system disorders | 31/50 | 24/48 | 22/47 |
| AlopeciaSkin and subcutaneous tissue disorders | 21/50 | 17/48 | 16/47 |
| LeukopeniaBlood and lymphatic system disorders | 16/50 | 20/48 | 10/47 |
| ConstipationGastrointestinal disorders | 19/50 | 19/48 | 14/47 |
| VomitingGastrointestinal disorders | 13/50 | 18/48 | 12/47 |
| ThrombocytopeniaBlood and lymphatic system disorders | 13/50 | 17/48 | 15/47 |
| CoughRespiratory, thoracic and mediastinal disorders | 16/50 | 11/48 | 10/47 |
| Age Continuous(years) | HER2+ | HER2- (Taxane-) | HER2- (Taxane+) | Total |
|---|---|---|---|---|
| Mean | 56.1 ± 9.45 | 55.7 ± 11.17 | 54.8 ± 9.92 | 55.55 ± 10.16 |
| Sex: Female, Male(Participants) | HER2+ | HER2- (Taxane-) | HER2- (Taxane+) | Total |
|---|---|---|---|---|
| Female | 50 | 51 | 49 | 150 |
| Male | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | HER2+ | HER2- (Taxane-) | HER2- (Taxane+) | Total |
|---|---|---|---|---|
| United States | 50 | 51 | 49 | 150 |
| Eastern Cooperative Oncology Group Performance Status(participants) | HER2+ | HER2- (Taxane-) | HER2- (Taxane+) | Total |
|---|---|---|---|---|
| 0 - Fully Active | 41 | 36 | 32 | 109 |
| 1 - Ambulatory, Restricted Strenuous Activity | 8 | 14 | 17 | 39 |
| 2 - Ambulatory, No Work Activities | 1 | 1 | 0 | 2 |
| Race/Ethnicity(participants) | HER2+ | HER2- (Taxane-) | HER2- (Taxane+) | Total |
|---|---|---|---|---|
| Caucasian | 31 | 42 | 36 | 109 |
| Black | 8 | 5 | 11 | 24 |
| Hispanic | 7 | 4 | 1 | 12 |
| Other | 4 | 0 | 1 | 5 |
The record gives a start of Apr 2004, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gemcitabine · Carboplatin